Open Access

Elevated CD44 expression predicts poor prognosis in patients with low‑grade glioma

  • Authors:
    • Qiang Dong
    • Qiao Li
    • Maolin Wang
    • Jianhong Hu
    • Junqiang Dai
    • Liang Niu
    • Guoqiang Yuan
    • Yawen Pan
  • View Affiliations

  • Published online on: August 7, 2019     https://doi.org/10.3892/ol.2019.10728
  • Pages: 3698-3704
  • Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

CD44 is involved in malignant processes including cell motility, tumor growth and angiogenesis. To explore the potential role of CD44 as a prognostic biomarker in low grade gliomas (LGG), the mRNA expression levels of CD44 in tissues from 12 patients with glioma were evaluated by microarray analysis. The mRNA level of CD44 in LGG and glioblastoma multiforme (GBM) were analyzed using datasets downloaded from the publicly available Oncomine database. Reverse transcription‑quantitative PCR and western blotting were used to further analyze the CD44 expression level in a set of 53 patients. Kaplan‑Meier analysis was performed to identify the prognostic roles of CD44 mRNA in LGG and GBM, with data obtained from the OncoLnc and Gene Expression Profiling Interactive Analysis databases and clinical follow‑ups. The present results revealed that CD44 mRNA expression levels were elevated in LGG and GBM compared with normal brain tissues. Furthermore, increased CD44 expression was associated with poor survival rates in LGG. The present study suggested that CD44 may act as an independent prognostic factor for LGG, and may be a potential therapeutic target for gliomas.

References

1 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarellabranger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol. 18 (Suppl_5):v1–v75. 2016. View Article : Google Scholar : PubMed/NCBI

3 

van den Bent MJ: Practice changing mature results of RTOG study 9802: Another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol. 16:1570–1574. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Behin A, Hoangxuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Roszkowski K, Furtak J, Zurawski B, Szylberg T and Lewandowska M: Potential role of methylation marker in glioma supporting clinical decisions. Int J Mol Sci. 17:18762016. View Article : Google Scholar

6 

Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H, Dai J, Zhou W and Pan Y: Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. J Neurooncol. 133:193–201. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 75:1560–1566. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Felsberg J, Wolter M, Seul H, Friedensdorf B, Göppert M, Sabel MC and Reifenberger G: Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 119:501–507. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Delgado-López PD and Corrales-García EM: Survival in glioblastoma: A review on the impact of treatment modalities. Clin Transl Oncol. 18:1062–1071. 2016. View Article : Google Scholar : PubMed/NCBI

10 

Phan K, Ng W, Lu VM, McDonald KL, Fairhall J, Reddy R and Wilson P: Association between IDH1 and IDH2 mutations and preoperative seizures in patients with low-grade versus high-grade glioma: A systematic review and meta-analysis. World Neurosurg. 111:e539–e545. 2018. View Article : Google Scholar : PubMed/NCBI

11 

Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, et al: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 9:287–300. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, Mcgirt MJ and Thompson RC: The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol. 121:359–364. 2015. View Article : Google Scholar : PubMed/NCBI

13 

Li G, Shen J, Cao J, Zhou G, Lei T, Sun Y, Gao H, Ding Y, Xu W, Zhan Z, et al: Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461. J Exp Clin Cancer Res. 37:782018. View Article : Google Scholar : PubMed/NCBI

14 

Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, Kato Y, Yamamoto T and Matsumura A: Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol. 33:107–116. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Gulluoglu S, Tuysuz EC and Sahin M: Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes. Brain Res 1700. 199–210. 2018.

16 

Valder CR, Liu JJ, Song YH and Luo ZD: Coupling gene chip analyses and rat genetic variances in identifying potential target genes that may contribute to neuropathic allodynia development. J Neurochem. 87:560–573. 2003. View Article : Google Scholar : PubMed/NCBI

17 

Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, Emam I, Farne A, Hastings E, Holloway E, et al: ArrayExpress update-an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res. 39(Database Issue): D1002–D1004. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Sedlazeck FJ, Lee H, Darby CA and Schatz MC: Piercing the dark matter: Bioinformatics of long-range sequencing and mapping. Nat Rev Genet. 19:329–346. 2018. View Article : Google Scholar : PubMed/NCBI

19 

Dalal S, Zha Q, Daniels CR, Steagall RJ, Joyner WL, Gadeau AP, Singh M and Singh K: Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress. Am J Physiol Heart Circ Physiol. 306:H1182–H1191. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Feng C, Zhang Y, Yin J, Li J, Abounader R and Zuo Z: Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma. Neuro Oncol. 16:1078–1085. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Monaghan M, Mulligan KA, Gillespie H, Trimble A, Winter P, Johnston PG and McCormick D: Epidermal growth factor up-regulates CD44-dependent astrocytoma invasion in vitro. J Pathol. 192:519–525. 2015. View Article : Google Scholar

22 

Zhao LH, Lin QL, Wei J, Huai YL, Wang KJ and Yan HY: CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression. Int J Clin Exp Pathol. 8:692–701. 2015.PubMed/NCBI

23 

Xu Y, Stamenkovic I and Yu Q: CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 70:2455–2464. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, et al: Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res. 30:253–259. 2010.PubMed/NCBI

25 

Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL and Chen ZP: TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro Oncol. 15:1353–1365. 2013. View Article : Google Scholar : PubMed/NCBI

26 

Nishikawa M, Inoue A, Ohnishi T, Kohno S, Ohue S, Matsumoto S, Suehiro S, Yamashita D, Ozaki S, Watanabe H, et al: Significance of Glioma Stem-Like cells in the tumor periphery that express high levels of CD44 in tumor invasion, early progression, and poor prognosis in glioblastoma. Stem Cells Int 2018. 53870412018.

27 

Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH and Kulkarni P: Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res. 73:4123–4133. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Guo JY, Hsu HS, Tyan SW, Li FY, Shew JY, Lee WH and Chen JY: Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner. Oncogene. 36:2457–2471. 2017. View Article : Google Scholar : PubMed/NCBI

29 

Zhao S, Chen C, Chang K, Karnad A, Jagirdar J, Kumar AP and Freeman JW: CD44 expression level and isoform contributes to pancreatic cancer cell plasticity, invasiveness and response to therapy. Clin Cancer Res. 22:5592–5604. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Wang HH, Liao CC, Chow NH, Huang LL, Chuang JI, Wei KC and Shin JW: Whether CD44 is an applicable marker for glioma stem cells. Am J Transl Res. 9:4785–4806. 2017.PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Dong, Q., Li, Q., Wang, M., Hu, J., Dai, J., Niu, L. ... Pan, Y. (2019). Elevated CD44 expression predicts poor prognosis in patients with low‑grade glioma. Oncology Letters, 18, 3698-3704. https://doi.org/10.3892/ol.2019.10728
MLA
Dong, Q., Li, Q., Wang, M., Hu, J., Dai, J., Niu, L., Yuan, G., Pan, Y."Elevated CD44 expression predicts poor prognosis in patients with low‑grade glioma". Oncology Letters 18.4 (2019): 3698-3704.
Chicago
Dong, Q., Li, Q., Wang, M., Hu, J., Dai, J., Niu, L., Yuan, G., Pan, Y."Elevated CD44 expression predicts poor prognosis in patients with low‑grade glioma". Oncology Letters 18, no. 4 (2019): 3698-3704. https://doi.org/10.3892/ol.2019.10728